Literature DB >> 32011081

Full robotic ALPPS for HCC with intrahepatic portal vein thrombosis.

Fabrizio Di Benedetto1, Giacomo Assirati1, Paolo Magistri1.   

Abstract

BACKGROUND: The associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique can induce a greater degree of hypertrophy of the future liver remnant (FLR) in a shorter time compared with other procedures. A robotic approach may reduce the complication rate, increasing the ability to perform classic ALPPS.
METHODS: We report technical and clinical considerations on the first full robotic ALPPS (stages 1 and 2) for hepatocellular carcinoma (HCC) with portal vein intrahepatic tumor thrombus.
RESULTS: The patient was a 38-year-old man with Milan-out HCC and FLR volume of 19.6%. On postoperative day (POD) 8, FLR increased to 37%; therefore, he underwent completion of ALPPS on POD 10. The postoperative course was uneventful, and the patient was discharged in good general conditions on POD 3.
CONCLUSION: Robotic ALPPS is safe and feasible for selected patients with initially unresectable HCC or requiring extended resections, with good postoperative outcomes.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  PVT; associating liver partition and portal vein ligation for staged hepatectomy; hepatocellular carcinoma; major hepatectomy; minimally invasive; robotic surgery; staged hepatectomy

Year:  2020        PMID: 32011081     DOI: 10.1002/rcs.2087

Source DB:  PubMed          Journal:  Int J Med Robot        ISSN: 1478-5951            Impact factor:   2.547


  2 in total

1.  First Case of Full Robotic ALPPS for Intrahepatic Cholangiocarcinoma.

Authors:  Fabrizio Di Benedetto; Paolo Magistri
Journal:  Ann Surg Oncol       Date:  2020-07-07       Impact factor: 5.344

Review 2.  Leaping the Boundaries in Laparoscopic Liver Surgery for Hepatocellular Carcinoma.

Authors:  Gianluca Cassese; Ho-Seong Han; Boram Lee; Hae Won Lee; Jai Young Cho; Roberto Troisi
Journal:  Cancers (Basel)       Date:  2022-04-15       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.